Indole-3-Carbinol.
Research-backed compound with potential health benefits. It shifts how your body routes oestrogen through its clearance pathways, and switches on the liver enzymes that handle everyday compounds. The routing change shows up in a urine marker.
Reviewed March 2026
- Category
- Compound
What Indole-3-Carbinol is, and what it does.
- Does it work
- Suits adults supporting the liver's normal clearance pathways, and women interested in how oestrogen is metabolised. People eating crucifers daily already get some of it.
- How much to take
- Start with 100 to 200mg a day, the daily maintenance band, taken with food. The 400mg used in studies is a research condition rather than a daily target.
- Time to feel it
- There's no sensation attached to it. The oestrogen metabolite ratio it gets measured by shifts over roughly four weeks of daily use.
- The first dose
- Day one is quiet. In the stomach it condenses within minutes into the molecules that do the work, and liver enzyme transcription starts moving, which is a lab reading rather than a feeling.
- With regular use
- Across four to eight weeks the urinary oestrogen metabolite ratio shifts and the liver's phase one and phase two enzymes stay upregulated. It reads on a lab report.
- How well tolerated
- Generally well tolerated at maintenance amounts, with mild stomach upset the usual complaint. Because it shifts liver enzyme activity, check with your doctor if you take prescription medicine.
- How it feels
- Honestly, it feels like nothing much. This is a biochemistry ingredient you judge from a urine or blood marker rather than from how your day goes.
- The overlooked benefit
- It doesn't exist until you cut or chew the vegetable, and stomach acid then converts most of it onward, so anything that lowers stomach acid changes what your dose becomes.
100 to 200mg a day is where Indole-3-Carbinol works.
Source: Bradlow et al. J Cell Biochem Suppl 1999; Reed et al. Nutr Cancer 2005
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Indole-3-Carbinol is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- oestrogen metabolite ratio in urineRandomised trial
- induction of liver biotransformation enzymesNarrative review
- condensation to diindolylmethane in gastric acidIn vitro study
- antioxidant enzyme expressionAnimal study
Questions people ask about Indole-3-Carbinol.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Indole-3-carbinol is acid-labile and condenses in the stomach to a mixture in which DIM is the main stable product. Most of what reaches circulation after an I3C dose is DIM, so the two sit on one continuum rather than acting independently.
Glucobrassicin is the parent glucosinolate that yields indole-3-carbinol once its thioglucoside bond is cleaved. Supplying the precursor and the free indole together covers both the rapid and the enzyme-dependent route.
Myrosinase is the plant enzyme that hydrolyses glucobrassicin to the unstable intermediate that rearranges to indole-3-carbinol. Without active myrosinase, conversion depends on gut bacteria and is far less predictable.
Both arise from cruciferous glucosinolates and both raise expression of phase II conjugating enzymes, sulforaphane mainly through Nrf2 and indole-3-carbinol also through the aryl hydrocarbon receptor. The two arms cover different enzyme sets in the same system.
Indole-3-carbinol raises glutathione S-transferase expression, and every conjugation that enzyme catalyses consumes a molecule of glutathione. Keeping the tripeptide pool supplied lets the induced enzyme work at capacity.
Cysteine availability sets the ceiling on glutathione synthesis, and NAC is the usual way to raise it. Pairing it with an inducer of glutathione-dependent conjugation supplies the raw material the induction calls for.
Indole-3-carbinol shifts oestrogen hydroxylation toward the 2-hydroxy route, and glucaro-1,4-lactone from calcium D-glucarate slows bacterial beta-glucuronidase so glucuronidated metabolites stay conjugated in the gut. One step changes which metabolite is formed, the other keeps it on its way out.
The 2-hydroxy catechol metabolites favoured by indole-3-carbinol are cleared by catechol-O-methyltransferase, which transfers a methyl group from S-adenosylmethionine. Methyl-group supply is what keeps that clearance step moving.
Folate in its methyl form feeds the remethylation cycle that regenerates S-adenosylmethionine after each COMT reaction. It supports the same methylation step that handles catechol oestrogen metabolites.
Catechol-O-methyltransferase is a magnesium-dependent enzyme, and methionine adenosyltransferase needs magnesium and ATP to make the methyl donor. Adequate magnesium is a quiet requirement of the whole methylation arm.
Indole-3-carbinol condensation products and tryptophan-derived indoles both bind the aryl hydrocarbon receptor. They draw on the same signalling node, so their effects on that receptor are not independent.
Indole-3-carbinol is not the molecule that persists after swallowing; gastric acid drives its condensation into diindolylmethane and larger oligomers, and that acid-catalysed step is the reason the compound behaves as it does. Betaine hydrochloride lowers gastric pH in people whose acid output is reduced. Where acid is low, the conversion is slower and the delivered profile shifts. This is chemistry of the stomach, not a claim about either ingredient.
Glutathione is a tripeptide of glutamate, cysteine and glycine, and glycine availability becomes limiting in some states. Indole-3-carbinol derivatives induce glutathione S-transferase activity, which consumes glutathione as the conjugating substrate. Raising the enzyme without the substrate is half a system. Glycine supplies one of the three required amino acids.
Cysteine is the rate-limiting amino acid for glutathione synthesis in most tissues. Indole-3-carbinol condensation products upregulate phase II conjugating enzymes that draw on the glutathione pool. The cofactor logic is direct: more conjugating capacity needs more conjugating substrate. Cysteine is unstable in solution and is usually supplied as N-acetylcysteine or from whey protein.
Selenium sits as selenocysteine at the active site of glutathione peroxidase, the enzyme that uses the glutathione pool to reduce peroxides. Indole-3-carbinol derivatives shift the balance of phase I and phase II enzyme activity, and phase I induction generates reactive intermediates that need handling. Selenium status determines how well that handling proceeds. This is settled nutritional enzymology.
Dihydrolipoic acid regenerates oxidised glutathione and other cellular reductants, keeping the redox pool in its usable form. Indole-3-carbinol chemistry draws on that pool through phase II conjugation. Lipoic acid works on recycling rather than on synthesis, which is a distinct contribution from the amino acid precursors. It is both water and lipid compatible, so it reaches both compartments.
Methylation is the second conjugation route for hydroxylated oestrogen metabolites, and catechol-O-methyltransferase depends on S-adenosylmethionine regenerated through the B12-dependent methionine synthase reaction. Indole-3-carbinol derivatives shift oestrogen hydroxylation toward the 2-hydroxy position, producing more catechol substrate for that methylation step. B12 deficiency constrains the downstream half of the pathway. This is textbook one-carbon biochemistry.
Riboflavin becomes FAD, the cofactor for methylenetetrahydrofolate reductase and for the flavin-containing monooxygenases and cytochrome P450 reductase that drive phase I oxidation. Indole-3-carbinol is a known inducer of CYP1A enzymes, which cannot turn over without an adequately flavinated reductase. The cofactor requirement is absolute rather than optional. Riboflavin status is rarely considered alongside this ingredient.
Choline is oxidised to betaine, which donates a methyl group to homocysteine through betaine-homocysteine methyltransferase, a folate-independent route to regenerating methionine. Methylation capacity is what conjugates the catechol oestrogen metabolites that indole-3-carbinol derivatives shift the balance toward. Choline supports the second half of that sequence. The relationship is metabolic, not a combination trial.
Trimethylglycine donates a methyl group directly to homocysteine, sustaining the S-adenosylmethionine pool that methyltransferases draw on. Catechol-O-methyltransferase is one of those enzymes and it acts on the 2-hydroxylated metabolites that indole-3-carbinol chemistry favours. Betaine works independently of folate status, which is the practical distinction from methylfolate. Note this is anhydrous betaine, not betaine hydrochloride.
Silymarin flavonolignans are described as supporting hepatic glutathione status and as modulating several phase I and phase II enzymes in preclinical work. Indole-3-carbinol acts on the same enzyme families through the aryl hydrocarbon receptor. The two converge on hepatic biotransformation from different receptor entry points. Overlapping enzyme modulation also means their effects on co-administered medicines are not independent.
EGCG is an inhibitor of catechol-O-methyltransferase in vitro, the enzyme that methylates 2-hydroxyoestrogen metabolites. Indole-3-carbinol derivatives increase the supply of exactly that substrate. Combining a substrate-increasing agent with an inhibitor of the enzyme that clears it is a directional interaction worth flagging rather than assuming is additive. The observation is laboratory-level and has not been measured as a combination in people.
Curcumin activates Nrf2 signalling, which transcribes the phase II battery including glutathione S-transferases and NAD(P)H quinone oxidoreductase. Indole-3-carbinol derivatives reach an overlapping enzyme set through aryl hydrocarbon receptor signalling. Two different transcriptional routes to a partly shared output is the reason they appear together. Curcumin absorption is poor without a lipid or piperine aid.
Quercetin inhibits several sulfotransferase and UDP-glucuronosyltransferase isoforms in vitro and is itself a substrate for them. Indole-3-carbinol shifts the phase I and phase II balance in the same hepatic compartment. Whether the net effect on any given metabolite rises or falls depends on which isoform dominates its clearance. The direction is not predictable from mechanism alone, which is the honest position.
Resveratrol inhibits CYP1A1 and CYP1B1 in laboratory systems, the same enzymes indole-3-carbinol induces through the aryl hydrocarbon receptor. That places them in direct opposition at one enzyme family while both are described as favourable in isolation. Stacking them is not simply additive. No human work has measured the combination.
Gut bacteria convert dietary tryptophan into indole derivatives that are themselves aryl hydrocarbon receptor ligands, the same receptor indole-3-carbinol condensation products engage. The microbiota therefore contributes its own baseline ligand load to that receptor. A supplemented indole adds to an existing microbial signal rather than acting on a blank receptor. The composition of that background varies from person to person.
Broccoli sprouts carry both glucobrassicin, the glucosinolate that yields indole-3-carbinol, and glucoraphanin, which yields sulforaphane. A whole sprout extract therefore delivers the indole and the isothiocyanate together, as the vegetable does. Sulforaphane acts through Nrf2 and the indole through the aryl hydrocarbon receptor. Combining an isolate with the extract raises the indole share of that natural ratio.
Pyridoxal 5-phosphate is the cofactor for cystathionine beta-synthase and cystathionine gamma-lyase, the transsulfuration steps that convert homocysteine into cysteine for glutathione synthesis. Phase II conjugation induced by indole chemistry draws on that glutathione. B6 status sets how much homocysteine can be routed toward cysteine rather than remethylated. The dependency is a defined enzymatic requirement.
Cruciferous extracts and the plant matrix they come from carry polyphenols and, in whole-vegetable preparations, goitrogenic constituents; the more general point is that concentrated plant fractions taken with an iron salt commonly reduce non-haem iron uptake through complexation in the gut lumen. Separating an iron dose from a concentrated plant extract by a couple of hours is standard practice. For a purified indole-3-carbinol isolate the concern is smaller than for a whole cruciferous concentrate. Direction of the effect is what matters here, not a number.
Whole cruciferous vegetables also yield thiocyanate and goitrin from other glucosinolates, and thiocyanate competes with iodide at the sodium-iodide symporter. A purified indole-3-carbinol isolate does not carry those compounds, so the concern belongs to whole cruciferous concentrates rather than to the isolate. Iodine sufficiency is what determines whether any competition matters. The distinction between isolate and whole-plant concentrate is the useful part.
Nothing specific on file for Indole-3-Carbinol. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Indole-3-Carbinol actually does.
Indole-3-carbinol is not present in intact cruciferous tissue; it is released when the enzyme myrosinase, held in separate cells, meets the glucosinolate glucobrassicin after the plant is cut, chewed or crushed.
In the acid environment of the stomach, indole-3-carbinol undergoes self-condensation to 3,3-diindolylmethane and to higher oligomers including indolo[3,2-b]carbazole, so the molecules reaching circulation are the condensation products rather than the parent compound.
Indolo[3,2-b]carbazole is a high-affinity ligand for the aryl hydrocarbon receptor; ligand binding releases the receptor from its chaperone complex, allows nuclear translocation and dimerisation with ARNT, and drives transcription at xenobiotic response elements.
That transcriptional programme includes the CYP1A1, CYP1A2 and CYP1B1 phase I monooxygenases together with phase II enzymes such as glutathione S-transferases and UDP-glucuronosyltransferases, so both arms of biotransformation move together rather than one in isolation.
Where Indole-3-Carbinol comes from.
Broccoli and its relatives do not contain this compound until you cut or chew them. Damage to the plant lets an enzyme meet a storage molecule, and indole-3-carbinol is what comes out of that reaction. Makers either run the same reaction on vegetable material at scale and purify what forms, or build the molecule from a simpler chemical starting point. Both end with the same white powder, kept dry because moisture and acid break it down.
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
Two distinct commercial routes exist. The plant route starts from broccoli, cabbage, Brussels sprout or mustard material rich in the glucosinolate glucobrassicin. The synthetic route starts from indole and builds the hydroxymethyl group at the 3 position.
On the plant route, cell disruption brings myrosinase into contact with glucobrassicin, releasing an unstable isothiocyanate that decomposes to indole-3-carbinol. On the synthetic route, indole undergoes hydroxymethylation, commonly through a Mannich-type intermediate that is then hydrolysed.
The indole is taken into an organic solvent away from sugars, salts and plant polymers; the same partitioning logic applies to both routes at this point.
Crude material is recrystallised from a suitable solvent system to raise assay purity, with the process kept cool and away from acid because the compound condenses readily.
Purity is set by HPLC against a reference standard and identity confirmed spectroscopically; residual solvent and heavy metal limits are part of the specification on either route.
Filled dry, often with a desiccant in the packaging, because the finished compound degrades on exposure to moisture and heat.
Getting Indole-3-Carbinol from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- Reviewing human and mechanistic work, glucosinolate breakdown products including indole-3-carbinol were linked with changes in detoxification enzyme activity and in lipid and glucose markers.Systematic review. Costa-Pérez et al., 2023 (Nutrients). PMID 36986155 ↗
- Dietary supplementation with diindolylmethane or indole-3-carbinol altered how quickly volunteers cleared an ingested tracer dose of benzo[a]pyrene.Randomised trial. Vermillion Maier et al., 2023 (Toxicology and applied pharmacology). PMID 36642108 ↗
- Across the human evidence, normal servings of brassica vegetables were not shown to disturb thyroid function, with concern limited to very high intakes alongside low iodine.Systematic review. Galanty et al., 2024 (International journal of molecular sciences). PMID 38612798 ↗
- In apoE-deficient mice fed a western-type diet, indole-3-carbinol was reported to reduce markers of endoplasmic reticulum stress and circulating leptin; these are animal biomarker measurements and not a human outcome.Animal study. Kim et al., 2026 (Food and Nutrition Research). PMID 41777238 ↗
- Working in porcine ovarian tissue exposed to Fenton reaction substrates, the authors report that indole-3-carbinol behaved as an antioxidant at some concentrations and increased lipid peroxidation at others, which is why they describe two faces of the compound.In vitro study. Skoczynska et al., 2025 (Nutrients). PMID 41097110 ↗
- A placebo-controlled study of diindolylmethane, the acid condensation product of indole-3-carbinol, in healthy BRCA gene carriers reported a change in a mammographic tissue density measure; density is an imaging marker rather than a clinical outcome.Randomised trial. Yerushalmi et al., 2020 (Carcinogenesis). PMID 32458980 ↗
- Cauliflower preparation, a Brassica source of the same indole glucosinolates, was reported to reduce aromatase activity in Sprague-Dawley rats; the finding is an animal enzyme measurement in a whole-vegetable preparation rather than in the isolated compound.Animal study. Pratama et al., 2025 (Open Veterinary Journal). PMID 42376534 ↗
- The authors describe tryptophan-derived indole metabolites acting through the aryl hydrocarbon receptor to drive interleukin-22 production in intestinal tissue, which places the indole class on a defined receptor pathway in the gut.Narrative review. Bantavi et al., 2026 (Cellular and Molecular Gastroenterology and Hepatology). PMID 41707749 ↗
- Food-derived aryl hydrocarbon receptor ligands are reported to be required for normal physiological activation of that receptor, supporting the idea that dietary indoles contribute a routine background signal at it.Narrative review. De Juan et al., 2026 (Nature Communications). PMID 41331250 ↗
- A metagenomic and metabolomic study in mice reports indole-3-ethanol, a related microbial indole, altering intestinal responses; the work is in animals and concerns a related indole rather than indole-3-carbinol itself.Animal study. Zhong et al., 2025 (Journal of Microbiology and Biotechnology). PMID 40730483 ↗
- The authors report a herbal formula altering intestinal bacteria and the aryl hydrocarbon receptor and reactive oxygen species pathway in an animal model; it is cited here only as it names the receptor pathway indole compounds act through.Animal study. Li et al., 2026 (Phytomedicine). PMID 41351981 ↗
These are the studies our verdict leans on, chosen from the 783 we read for Indole-3-Carbinol. The full linked list is below.
The studies, linked.
9 sources behind our Indole-3-Carbinol verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialEffects of Bassica or Indole-3-Carbinol on Prostatectomy Patients With PSA RecurrenceClinicalTrials.gov ↗NA · 66 participants · Completed
- Clinical trialEffects of Dietary Indole-3-Carbinol on Estrogen Metabolites Across a Wide Range of Body Mass Index: Implications for the Prevention of Endometrial Cancer in Obese WomenClinicalTrials.gov ↗PHASE2 · 38 participants · Terminated
- ClinicalTrials.gov ↗
- Clinical trialMultiple Daily Dose Phase I Safety And Pharmacokinetic Clinical Study Of Indole-3-CarbinolClinicalTrials.gov ↗PHASE1 · 17 participants · Completed
- Clinical trialEffects of Brassica or Indole-3-Carbinol on Prostatectomy Patients With PSA RecurrencClinicalTrials.gov ↗PHASE2 · 16 participants · Completed
- Clinical trialPhase I Ascending Single Dose Pharmacokinetics (PK) and Safety Study of 3,3' Di-Indolymethane (DIM) Nutritional ProductClinicalTrials.gov ↗PHASE1 · Completed
- Clinical trialAirway Intervention Registry (AIR) Extension: Recurrent Respiratory PapillomatosisClinicalTrials.gov ↗400 participants · Unknown
- Clinical trialA Prospective, Multicenter, Randomized, Open-label, Superiority Clinical Trial With an Umbrella Trial Design Framework to Evaluate the Efficacy of a Precision Treatment Strategy Guided by Multiple Biomarkers in the First-line Therapy of Advanced Esophageal Squamous Cell CarcinomaClinicalTrials.gov ↗PHASE2 · 347 participants · Not yet recruiting
- Clinical trialProspective, Multicenter, Open-label, Randomized, Parallel Groups Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules (LLC Alcea, Russia) and Visanne 2 mg Tablets (BAYER AG, Germany) in Treatment of EndometriosisClinicalTrials.gov ↗PHASE3 · 290 participants · Recruiting
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Problems people have reported.
Read this carefully. These are 158 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Indole-3-Carbinol is, not how risky it is. A report is not proof Indole-3-Carbinol caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.